127792-33-0

Basic information

• Product Name: 2-[(3,4-Dichlorophenyl)amino]benzeneacetic acid
• Synonyms: 2-(3,4-Dichlorophenylamino)benzeneacetic acid;2-[(3,4-Dichlorophenyl)amino]benzeneacetic acid
• CAS NO: 127792-33-0
• Molecular Formula: C₁₄H₁₁Cl₂NO₂
• Molecular Weight: 296.15
• Mol File: 127792-33-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[(3,4-Dichlorophenyl)amino]benzeneacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(3,4-Dichlorophenyl)amino]benzeneacetic acid(127792-33-0)
• EPA Substance Registry System: 2-[(3,4-Dichlorophenyl)amino]benzeneacetic acid(127792-33-0)

Safety Data

• Hazardous Substances Data: 127792-33-0(Hazardous Substances Data)

Usage

General Description

2-[(3,4-Dichlorophenyl)amino]benzeneacetic acid, also known as Diclofenac, is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used to relieve pain and reduce inflammation. It works by inhibiting the enzyme cyclooxygenase (COX), which is responsible for the production of prostaglandins, hormone-like substances that play a role in pain and inflammation. Diclofenac is often prescribed to treat conditions such as arthritis, menstrual cramps, and acute injuries. It can be taken orally in the form of tablets or applied topically as a gel or patch. However, it is important to use this medication as directed by a healthcare professional due to potential side effects and interactions with other medications.

Upstream product

• 75117-26-9 N,N-dimethyl-2-(2-vinylphenyl)acetamide 
• 95-76-1 m,p-dichloroaniline 

Relevant articles and documents

Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies

The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin,, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.

Synthesis and quantitative structure-activity relationships of diclofenac analogues

The synthesis of a series of 2-anilinophenylacetic acid, close analogues of diclofenac, is described. These compounds were tested in two models used for evaluating the activity of nonsteroidal antiinflammatory drugs (NSAID's), inhibition of cyclooxygenase enzyme activity in vitro, and adjuvant-induced arthritis (AdA) in rats. Statistically significant correlations were found between the inhibitory activities of the compounds in these two models, indicating that cyclooxygenase inhibition seems to be the underlying mechanism for the antiinflammatory activity of these compounds. Quantitative structure-activity relationship (QSAR) analysis revealed that the crucial parameters for activity in both models were the lipophilicity and the angle of twist between the two phenyl rings. Optimal activities were associated with halogen or alkyl substituents in both ortho positions of the anilino ring. Compounds with OH groups in addition to two ortho substituents or compounds with only one or no ortho substituents were less active.